| Date | Title | | | 11/21/07 | GTx Announces Webcast of Corporate Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 21, 2007--GTx, Inc. (Nasdaq:
GTXI) announced today that management will present a company overview
at the Lazard Capital Markets Fourth Annual Healthcare Conference on
November 28 in New York City. The GTx presentation will begin at 10:00
a.m. Eastern Time. A simultaneous webcast of the presentation will be
accessible from the GTx website at www.gtxinc.com. An archived replay
of the presentation will be available on the company website until
Decem... |
|  | | 11/12/07 | GTx Announces Webcast of Corporate Presentation at the Citi Biotech Day Investor Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 12, 2007--GTx, Inc. (Nasdaq:
GTXI) announced the webcast of its presentation this morning at the
Citi Biotech Day investor conference. The presentation is scheduled to
begin at 10:45 a.m. Eastern Time. GTx senior management will provide a
company update and discuss GTx's clinical development programs. A
simultaneous webcast of the presentation will be available from the
GTx website at www.gtxinc.com. An archived replay of the presentation
will be ... |
| | | 11/08/07 | GTx to Participate in the Citi Biotech Day Investor Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 8, 2007--GTx, Inc. (Nasdaq:
GTXI) announced today that it will participate in the Citi Biotech Day
investor conference on November 12, 2007 at 10:45 a.m. Eastern Time.
GTx senior management will provide a company update and discuss GTx's
clinical development programs.
CONTACT: GTx, Inc.
McDavid Stilwell, 901-523-9700
Director, Corporate Communications & Financial Analysis
SOURCE: GTx, Inc.
... |
| | | 11/06/07 | GTx, Inc. Reports Third Quarter 2007 Financial Results| MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 6, 2007--GTx, Inc. (NASDAQ:
GTXI) today reported financial results for the third quarter of 2007.
The net loss for the third quarter and nine months ended September 30,
2007, was $10.2 million and $27.6 million, respectively, compared with
a net loss of $10.9 million and $30.8 million for the same periods in
2006. At September 30, 2007, GTx had cash and cash equivalents of
$90.9 million.
"GTx's clinical development programs continued to make g... |
| | | 11/06/07 | GTx, Inc. and Merck & Co., Inc. Enter Global Strategic Collaboration for the Development of SARMs, a Novel Investigational Class of Drugs to Treat Muscle Loss and other Musculoskeletal Conditions| MEMPHIS, Tenn. & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI - News) and Merck & Co., Inc. (NYSE: MRK - News) today announced an agreement providing for a research and development and global strategic collaboration for selective androgen receptor modulators (SARMs), a new class of drugs with the potential to treat age-related muscle loss (sarcopenia) as well as other musculoskeletal conditions. This collaboration includes GTx's lead SARM candidate, Ostarine™, which is curr... |
| | | 10/31/07 | GTx Announces Presentations at CIBC World Markets Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw Annual Healthcare Conference| MEMPHIS, Tenn., Oct 31, 2007 (BUSINESS WIRE) -- GTx, Inc. (Nasdaq: GTXI) announced today that management will
present a company overview on November 7, 2007 at two investor
conferences in New York City. GTx management will speak at the 18th
Annual CIBC World Markets Healthcare Conference beginning at 9:45 a.m.
Eastern Time and at the Acumen BioFin Rodman & Renshaw 9th Annual
Healthcare Conference beginning at 1:20 p.m. Eastern Time. A
simultaneous webcast of each of the presentations will ... |
| | | 10/23/07 | GTx, Inc. Announces Third Quarter 2007 Financial Results Conference Call and Webcast| MEMPHIS, Tenn.--(BUSINESS WIRE)--Oct. 23, 2007--GTx, Inc. (Nasdaq:
GTXI), today announced that it will host a conference call and webcast
to discuss the Company's third quarter 2007 financial results on
Tuesday, November 6 at 9:00 a.m. Eastern. The call and webcast will
follow the release of the third quarter 2007 financial results earlier
that day.
To listen to the conference call, please dial:
-- 800-901-5248 from the United States and Canada or
-- 617-786-... |
| | | 09/18/07 | GTx to Present at the UBS Global Life Sciences Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--Sept. 18, 2007--GTx, Inc.
(Nasdaq: GTXI) announced today that management will present a company
overview on September 25 at the UBS Global Life Sciences Conference in
New York City. The GTx presentation will begin at 4:00 p.m. Eastern
Time. A simultaneous webcast of the presentation will be accessible
from the investor relations section of the GTx website at
www.gtxinc.com. An archived replay of the presentation will be
available on the company website... |
| | | 09/11/07 | GTx Announces Webcast of Corporate Presentation at the A.G. Edwards Emerging Growth Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--Sept. 11, 2007--GTx, Inc.
(Nasdaq: GTXI) announced today that management will present a company
overview at the A.G. Edwards Emerging Growth Conference on September
18 in New York City. The GTx presentation will begin at 8:30 a.m.
Eastern Time. A simultaneous webcast of the presentation will be
accessible from the GTx website at www.gtxinc.com. An archived replay
of the presentation will be available on the company website until
October 2.
About G... |
| | | 08/30/07 | GTx Announces Webcast of Corporate Presentation at the BioCentury NewsMakers in the Biotech Industry Conference| MEMPHIS, Tenn., Aug 30, 2007 (BUSINESS WIRE) -- GTx, Inc. (Nasdaq: GTXI) announced today that management will
present a company overview at the BioCentury NewsMakers in the Biotech
Industry Conference on September 6 at the Millennium Broadway Hotel in
New York City. The GTx presentation will begin at 11 a.m. Eastern
Time. A simultaneous webcast of the presentation will be accessible
from the GTx website at www.gtxinc.com. An archived replay of the
presentation will be available on the comp... |
| | | 07/31/07 | GTx, Inc. Reports Second Quarter 2007 Financial Results| MEMPHIS, Tenn.--(BUSINESS WIRE)--July 31, 2007--GTx, Inc. (NASDAQ:
GTXI) today reported financial results for the second quarter of 2007.
The net loss for the second quarter and six months ended June 30, 2007
was $9.2 million and $17.3 million, respectively, compared with a net
loss of $10.0 million and $19.9 million for the same periods in 2006.
At June 30, 2007, GTx had cash and cash equivalents of $102.0 million.
"We are pleased with the progress of the two ACAPODENE clinical
d... |
| | | 07/17/07 | GTx, Inc. Announces Second Quarter 2007 Financial Results Conference Call and Webcast| MEMPHIS, Tenn.--(BUSINESS WIRE)--July 17, 2007--GTx, Inc. (Nasdaq:
GTXI), today announced that it will host a conference call and webcast
to discuss the Company's second quarter 2007 financial results on
Tuesday, July 31 at 9:00 a.m. Eastern. The call and webcast will
follow the release of the second quarter 2007 financial results
earlier that day.
To listen to the conference call, please dial:
-- 800-237-9752 from the United States and Canada or
-- 617-847-8706 (International)
... |
| | | 07/12/07 | GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review| MEMPHIS, Tenn.--(BUSINESS WIRE)--July 12, 2007--GTx, Inc. (Nasdaq:
GTXI), today announced that a per protocol interim safety review by an
independent Data Safety Monitoring Board (DSMB) recommended that GTx
continue clinical development as planned with its two pivotal Phase
III clinical trials of ACAPODENE(R) (toremifene citrate). The DSMB
meets regularly every six months to review unblinded safety data from
the two pivotal Phase III clinical trials.
"The DSMB reviewed safety data... |
| | | 07/03/07 | GTx Initiates Phase IIb Ostarine Clinical Trial For Cancer Cachexia| MEMPHIS, Tenn.--(BUSINESS WIRE)--July 3, 2007--GTx, Inc. (Nasdaq:
GTXI), announced today that it has initiated the Phase IIb clinical
trial evaluating Ostarine(TM), a selective androgen receptor
modulator, or SARM, for the treatment of cancer cachexia.
"We are pleased to initiate the Ostarine Phase IIb cancer cachexia
clinical trial on schedule," said Mitchell S. Steiner, MD, Chief
Executive Officer of GTx. "Cancer cachexia, as a large unmet medical
need, is an important first ind... |
| | | 06/05/07 | GTx Announces Webcast of Corporate Presentation at Goldman Sachs 28th Annual Global Healthcare Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--June 5, 2007--GTx, Inc. (Nasdaq:
GTXI), announced today that management will present a company overview
at the Goldman Sachs 28th Annual Health Care Conference on June 12,
2007 at the Ritz Carlton in Laguna Niguel, California. The GTx
presentation will begin at 11:00 a.m. Pacific. A live webcast of the
presentation may be accessed by visiting the GTx website at
www.gtxinc.com. An archived replay of the webcast will be available
for two weeks beginning ... |
| | | 05/31/07 | GTx Announces Podium Presentation of SARM Preclinical and Clinical Trial Data at Endocrine Society's 2007 Annual Meeting| MEMPHIS, Tenn.--(BUSINESS WIRE)--May 31, 2007--GTx, Inc., (Nasdaq:
GTXI) announced today that James T. Dalton, PhD, Vice President of
Preclinical Research and Development at GTx, has been invited by the
Endocrine Society to deliver a podium presentation on the discovery,
clinical development, and therapeutic potential of selective androgen
receptor modulators (SARMs) at the 2007 Annual Meeting of the
Endocrine Society at the Metro Center in Toronto, Canada.
Dr. Dalton, who along w... |
| | | 05/25/07 | GTx Announces Presentation of Ostarine(TM) and ACAPODENE(R) Data at 2007 ASCO Annual Meeting| MEMPHIS, Tenn.--(BUSINESS WIRE)--May 25, 2007--GTx, Inc., (NASDAQ:
GTXI) announced today that data from the recent Phase II proof of
concept clinical trial of Ostarine(TM) and from the ongoing Phase III
clinical trial evaluating ACAPODENE(R) (toremifene citrate) 80 mg for
the treatment of multiple side effects of androgen deprivation therapy
(ADT) will be presented at the upcoming 2007 Annual Meeting of the
American Society of Clinical Oncology being held June 1 - 5 at
McCormick Place... |
| | | 05/23/07 | GTx Announces Webcast of Corporate Presentation at Bank of America 2007 Health Care Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--May 23, 2007--GTx, Inc. (Nasdaq:
GTXI), announced today that management will present a company overview
at the Bank of America 2007 Health Care Conference on May 30, 2007 at
the Four Seasons Hotel in Las Vegas. The GTx presentation will begin
at 5:20 p.m. Pacific. A live webcast of the presentation may be
accessed by visiting the GTx website at www.gtxinc.com. An archived
replay of the webcast will be available for two weeks beginning
approximately 1 h... |
| | | 05/17/07 | GTx Announces Webcast of Corporate Presentation at Citigroup Global Healthcare Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--May 17, 2007--GTx, Inc. (Nasdaq:
GTXI), announced today that management will present a company overview
at the Citigroup Global Healthcare Conference on May 24, 2007 at the
Hilton Hotel in New York City. The GTx presentation will begin at 8:00
a.m. Eastern. A live webcast of the presentation may be accessed by
visiting the GTx website at www.gtxinc.com. An archived replay of the
webcast will be available for two weeks beginning approximately 1 hour
aft... |
| | | 05/04/07 | GTX, Inc. Reports First Quarter 2007 Financial Results| MEMPHIS, Tenn.--(BUSINESS WIRE)--May 4, 2007--GTx, Inc. (Nasdaq:
GTXI) today reported financial results for the first quarter of 2007.
The net loss for the quarter ended March 31, 2007 was $8.1 million,
compared with a net loss of $9.9 million for the same period in 2006.
At March 31, 2007, GTx had cash and cash equivalents of $111.4
million.
"In the first quarter, GTx continued to make steady progress in
its clinical development programs. The two Phase III ACAPODENE trials
are p... |
| | | 04/20/07 | GTx, Inc. Announces First Quarter 2007 Financial Results Conference Call and Webcast| MEMPHIS, Tenn.--(BUSINESS WIRE)--April 20, 2007--GTx, Inc.
(Nasdaq: GTXI), today announced that it will host a conference call
and webcast to discuss the Company's first quarter 2007 financial
results on Friday, May 4 at 9:00 a.m. Eastern. The call and webcast
will follow the release of the first quarter 2007 financial results
earlier that day.
To listen to the conference call, please dial:
-- 866-202-0886 from the United States and Canada or
-- 617-213-8841 (Interna... |
| | | 04/17/07 | GTx Announces Ostarine(TM) Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial| MEMPHIS, Tenn.--(BUSINESS WIRE)--April 17, 2007--GTx, Inc.
(NASDAQ: GTXI) announced today that data from a recently conducted
Phase II Ostarine(TM) clinical trial of 60 elderly men and 60
postmenopausal women revealed that insulin and glucose levels were
reduced and insulin resistance was improved among subjects receiving
the 3 mg dose of Ostarine compared to baseline. These observations
were even more pronounced among a subset of prediabetic subjects.
Data from the Phase II clini... |
| | | 04/11/07 | GTx to Host an Analyst Day to Provide an Update on ACAPODENE Phase III Clinical Programs and Information on the Clinical Development and Commercialization Strategy for Ostarine| MEMPHIS, Tenn.--(BUSINESS WIRE)--April 11, 2007--GTx, Inc.
(Nasdaq: GTXI) announced today that at an Analyst Day meeting to be
held 11 a.m. to 2 p.m. on April 17 in New York City, the company will
present an update of the pivotal Phase III ACAPODENE(R) clinical
trials and information about its clinical development and
commercialization plans for Ostarine(TM), its first-in-class selective
androgen receptor modulator (SARM).
Dr. Matthew Smith, Associate Professor of Medicine at Harv... |
| | | 04/10/07 | GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory Affairs| MEMPHIS, Tenn.--(BUSINESS WIRE)--April 10, 2007--GTx, Inc.
(Nasdaq: GTXI) announced today the appointment of Jeff Hesselberg as
Vice President of Regulatory Affairs.
"Jeff Hesselberg brings additional strong regulatory expertise and
leadership at a critical time for GTx as we prepare for the potential
filings of New Drug Applications for ACAPODENE and as we advance
Ostarine into late stage clinical trials," said Mitchell S. Steiner,
M.D., Chief Executive Officer of GTx.
Mr. H... |
| | | 04/04/07 | GTx, Inc. Appoints Ronald A. Morton, Jr. MD, FACS as Chief Medical Officer| MEMPHIS, Tenn., Apr 04, 2007 (BUSINESS WIRE) -- GTx, Inc. (Nasdaq: GTXI) announced today the appointment of Ronald
A. Morton, Jr., M.D., F.A.C.S. as Chief Medical Officer.
"Ron Morton's appointment as Chief Medical Officer further
strengthens GTx's management team, and he will provide outstanding
medical leadership as we execute our commercialization plans for
ACAPODENE and Ostarine," said Mitchell S. Steiner, M.D., Chief
Executive Officer of GTx. "Dr. Morton is an excellent fit for our
c... |
| | | 03/22/07 | GTx Announces Webcast of Corporate Presentation at the Future Leaders in the Biotech Industry Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--March 22, 2007--GTx, Inc.
(Nasdaq: GTXI), announced today that management will present a company
overview at the Future Leaders in the Biotech Industry Conference on
March 29, 2007 at the Millennium Broadway Hotel & Conference Center in
New York City. The GTx presentation will begin at 4:00 p.m. Eastern
and will be simultaneously webcast. The link for the live webcast is
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=GTXI&item_id=
1492751. (D... |
| | | 03/16/07 | GTx Announces Webcast of Corporate Presentation at the 10th Annual Lehman Brothers Healthcare Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--March 16, 2007--GTx, Inc.
(Nasdaq: GTXI), announced today that management will present a company
overview at the 10th Annual Lehman Brothers Healthcare Conference on
March 20, 2007 at the Loews Miami Beach Hotel. The GTx presentation
will begin at 10:45 a.m. Eastern and will be simultaneously webcast.
The link for the live webcast is
http://cc.talkpoint.com/LEHM002/031907a_jw/default.asp?entity=GTX. The
presentation will also be accessible from the GTx... |
| | | 03/06/07 | GTx Announces Webcast of Corporate Presentation at the 27th Annual Cowen and Company Health Care Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--March 6, 2007--GTx, Inc. (Nasdaq:
GTXI), announced today that management will present a company overview
at the 27th Annual Cowen and Company Health Care Conference on March
13, 2007 at the Boston Marriott Copley Place hotel. The GTx
presentation will begin at 8:45 a.m. Eastern and will be
simultaneously webcast. The link for the live webcast is
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=GTXI&item_id=
1491104 (Due to the length of this UR... |
| | | 02/23/07 | GTx's ACAPODENE Interim Bone Mineral Density and Lipid Data Highlighted at Press Briefing at Prostate Cancer Symposium of the American Society of Clinical Oncology| ORLANDO--(BUSINESS WIRE)--Feb. 23, 2007--GTx, Inc. (NASDAQ: GTXI),
announced that a press briefing held this morning by the American
Society of Clinical Oncology (ASCO) at its annual Prostate Cancer
Symposium highlighted Phase III interim data revealing oral, once
daily ACAPODENE(R) (toremifene citrate) 80mg increases bone mineral
density and lowers cholesterol in prostate cancer patients on androgen
deprivation therapy. The two interim analyses were conducted in the
first 197 men who... |
| | | 02/21/07 | GTx Announces Presentation of ACAPODENE Data At ASCO Prostate Cancer Symposium| MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 21, 2007--GTx, Inc. (Nasdaq:
GTXI), today announced that Phase III data from a bone mineral density
interim analysis and from a lipid interim analysis will be presented
in separate podium sessions on February 23rd at the American Society
of Clinical Oncology Prostate Cancer Symposium. Both analyses were
conducted in the first 197 men to complete one year of treatment in
the Phase III clinical trial evaluating ACAPODENE(R) (toremifene
citrate) 80 m... |
| | | 02/20/07 | GTx Reports Fourth Quarter and Year End 2006 Results| MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 20, 2007--GTx, Inc. (Nasdaq:
GTXI), today reported financial results for the fourth quarter and
year ended December 31, 2006. The net loss for the three months and
year ended December 31, 2006 was $4.7 million and $35.5 million,
respectively, compared with a net loss of $7.8 million and $36.8
million for the same periods in 2005. At December 31, 2006, GTx had
cash and cash equivalents of $119.6 million.
"2006 was an outstanding year for GTx," ... |
| | | 02/14/07 | MacroArray Technologies Announces the Identification of a Urine Diagnostic Marker for High Grade PIN, a Precancerous Prostate Lesion| PHILADELPHIA--(BUSINESS WIRE)--Feb. 14, 2007--MacroArray
Technologies, LLC, today announced the identification of a novel urine
protein called ABCA5 as a sensitive diagnostic marker for high grade
prostatic intraepithelial neoplasia (PIN), the precancerous lesion of
the prostate. Details of the marker's identification were published in
the February issue of Clinical Cancer Research.
Men with high grade PIN are at the highest risk for developing
prostate cancer with approximately 5... |
| | | 02/09/07 | GTx, Inc. Announces Fourth Quarter and Year End 2006 Financial Results Conference Call and Webcast| MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 9, 2007--GTx, Inc. (Nasdaq:
GTXI), today announced that it will host a conference call and webcast
to discuss the Company's fourth quarter and year end 2006 financial
results on Tuesday, February 20 at 9:00 a.m. Eastern. The call and
webcast will follow the release of the fourth quarter and year end
2006 financial results earlier that day.
To listen to the conference call, please dial:
800-638-5439 from the United States and Canada or
... |
| | | 02/07/07 | GTx Announces Webcast of Corporate Presentation at the 9th Annual BIO CEO & Investor Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 7, 2007--GTx, Inc. (Nasdaq:
GTXI), announced today that management will participate in a panel
discussion and present a company overview at the 9th Annual BIO CEO &
Investor Conference on February 14, 2007. The panel discussion, which
will focus on issues related to prostate cancer, will begin at 9 a.m.
The presentation of the GTx company overview will begin at 11:15 a.m.
and will be simultaneously webcast. The link for the live webcast is
http://... |
| | | 02/02/07 | GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review| MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 2, 2007--GTx, Inc.
(NASDAQ:GTXI), the Men's Health Biotech Company, today announced that
a per protocol interim safety review by an independent Data Safety
Monitoring Board (DSMB) recommended that GTx continue clinical
development as planned with its two pivotal Phase III clinical trials
of ACAPODENE(R) (toremifene citrate). The DSMB meets regularly every
six months to review unblinded safety data from the two pivotal Phase
III clinical trials.
... |
| | | 01/04/07 | GTx Announces Webcast of Corporate Presentation at the JP Morgan 25th Annual Healthcare Conference| MEMPHIS, Tenn.--(BUSINESS WIRE)--Jan. 4, 2007--GTx, Inc. (Nasdaq:
GTXI), the Men's Health Biotech Company, announced today that
management will present a company overview at the JP Morgan 25th
Annual Healthcare Conference at noon Pacific time on January 11, 2007.
The presentation will be simultaneously webcast. The link for the live
webcast is www.events.jpmorgan.com. The presentation will also be
accessible from the GTx website at www.gtxinc.com. An archived replay
will be available ... |
| |
|
Print Page
E-mail Page
RSS Feeds
E-mail Alerts
IR Contacts
Financial Tear Sheet
